The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
- PMID: 29631132
- DOI: 10.1016/j.ejmech.2018.03.062
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Abstract
Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly haematopoietic malignancies and autoimmune diseases related to B lymphocytes. This review focuses on the diverse, small-molecule inhibitors of BTK kinase that have shown good prospects for clinical application. Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed. Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK. The present review also surveys the pharmacological advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire critical thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.
Keywords: Bruton's tyrosine kinase (BTK); Irreversible inhibitor; Kinase inhibitor; Reversible covalent inhibitor.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Bruton's TK inhibitors: structural insights and evolution of clinical candidates.Future Med Chem. 2014 Apr;6(6):675-95. doi: 10.4155/fmc.14.24. Future Med Chem. 2014. PMID: 24895895 Review.
-
Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.Eur J Med Chem. 2021 May 5;217:113329. doi: 10.1016/j.ejmech.2021.113329. Epub 2021 Mar 12. Eur J Med Chem. 2021. PMID: 33740548 Review.
-
Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.J Med Chem. 2015 Jul 23;58(14):5437-44. doi: 10.1021/acs.jmedchem.5b00734. Epub 2015 Jul 2. J Med Chem. 2015. PMID: 26087137
-
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.Eur J Med Chem. 2017 May 5;131:107-125. doi: 10.1016/j.ejmech.2017.03.001. Epub 2017 Mar 2. Eur J Med Chem. 2017. PMID: 28315597
-
Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.Bioorg Med Chem. 2015 Feb 15;23(4):891-901. doi: 10.1016/j.bmc.2014.10.043. Epub 2014 Nov 6. Bioorg Med Chem. 2015. PMID: 25596757
Cited by
-
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.Cancers (Basel). 2021 Mar 4;13(5):1103. doi: 10.3390/cancers13051103. Cancers (Basel). 2021. PMID: 33806595 Free PMC article. Review.
-
Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling.Molecules. 2023 Jan 17;28(3):943. doi: 10.3390/molecules28030943. Molecules. 2023. PMID: 36770611 Free PMC article. Review.
-
Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein.Angew Chem Int Ed Engl. 2021 Dec 6;60(50):26105-26114. doi: 10.1002/anie.202109464. Epub 2021 Nov 5. Angew Chem Int Ed Engl. 2021. PMID: 34590387 Free PMC article.
-
Bruton tyrosine kinase inhibitors for multiple sclerosis.Nat Rev Neurol. 2023 May;19(5):289-304. doi: 10.1038/s41582-023-00800-7. Epub 2023 Apr 13. Nat Rev Neurol. 2023. PMID: 37055617 Free PMC article. Review.
-
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae.Front Pharmacol. 2021 Jan 13;11:625498. doi: 10.3389/fphar.2020.625498. eCollection 2020. Front Pharmacol. 2021. PMID: 33519491 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Miscellaneous
